ClinicalTrials.gg

Program

Factor X

Its studies are mostly in Blood Coagulation Disorders, led by Kedrion.

Furthest: phase 3, since Apr 14, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kedrion10 open or runningphase 3since Apr 14, 2025Apr 14, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2025First study: phase 3 study in Factor X DeficiencyFirst studyNCT06963216

TargetBeta

F10 →read by rule
“Coagulation factor X exogenous protein”ChEMBL 37, by rule

Other programs on F10

ProgramCompanyFurthest phaseStudies
RivaroxabanruleBayerphase 477
apixabanruleBristol-Myers Squibbphase 444
emicizumabruleHoffmann-La Rochephase 413

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06963216Factor X Deficiency3WithdrawnJun 10, 20260

How it is read

Names in the registry

  • “Coagadex(R)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.